Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2− breast cancers by the 2015 St. Gallen consensus classification
Open Access
- 6 January 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-8
Abstract
This study evaluated the distribution pattern of the Ki67-labeling index (LI) among patients at a Chinese breast cancer center, and analyzed its prognostic significance in the 2015 St Gallen consensus breast cancer classification, estrogen receptor-positive and human epidermal growth factor receptor 2-negative(ER+/HER2−)subtype. We classified 939 women with ER+/HER2− breast cancer into three groups by Ki67-LI levels, and followed their clinicopathologic characteristics and prognoses. In the 939 eligible subjects, 342 had Ki67-LI ≤10% (Ki67Low), 281 had Ki67-LI between 10 and 30% (Ki67Medium), and 316 had Ki67-LI ≥30% (Ki67High). Although the Ki67High group had less favorable clinicopathologic factors, the Ki67Medium group’s factors varied considerably. Kaplan-Meier estimates showed that disease-free survival(DFS) for the Ki67Medium group was significantly shorter than the Ki67Low group but longer than the Ki67High group. Ki67-LI had independent prognostic significance in multivariate analysis. Other diagnostic factors, including tumor size >2 cm, positive lymph nodes, and grade III disease, were significantly associated with poorer disease-free survival only in the Ki67Medium group. For patients with ER+/HER2− breast cancer, we confirmed three distinct risk patterns by Ki67-LI levels according to the 2015 St Gallen consensus. For patients with clearly low or high Ki67-LI, straightforward clinical decisions could be offered, but for patients with intermediate Ki67-LI, other factors might provide valuable information.Keywords
Funding Information
- the National Natural Science Foundation of China under Grant (81372817)
This publication has 30 references indexed in Scilit:
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Annals of Oncology, 2015
- Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future PerspectivesJournal of Clinical Oncology, 2014
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort studyBMC Cancer, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Molecular portraits of human breast tumoursNature, 2000